213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
about
Targeted radionuclide therapies for pancreatic cancerLong-Term Toxicity of 213Bi-Labelled BSA in MiceSomatostatin receptor based imaging and radionuclide therapy.²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceInfluence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateTargeted alpha-therapy: past, present, future?Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.Bifunctional chelates for metal nuclides.Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine.Radionuclide therapy via SSTR: future aspects from experimental animal studies.Tumour targeting with radiometals for diagnosis and therapy.Matching chelators to radiometals for radiopharmaceuticals.In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.Radiolabeled peptides: valuable tools for the detection and treatment of canceralpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.Nuclear medicine imaging and therapy of neuroendocrine tumours.Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.
P2860
Q26801364-577E2A3D-E9C6-4F3E-A433-0A2783B187FDQ27317386-A9ED302A-D4EA-48E9-AEDE-32297ECDD91BQ35296661-BFDD7C58-5D8E-4952-9527-3BA83DD5FD5AQ35917106-B38AAFCB-AC76-44F6-AA31-723640AC671BQ36484229-CEE05673-FA36-4217-B2BB-9FE73E58F949Q36691184-1B68D547-C7B8-422B-8968-337FD5F9A506Q36778741-B4522B24-55B1-44B9-95AB-B37E2C737744Q37017010-98FCCA07-23B0-4EAF-BFF3-55BB89511066Q37427273-83634B43-CEA3-4382-8821-8A0509D58DD4Q38008839-B5776E49-A069-4699-8440-C9ECEBB6566FQ38100112-2C816DA3-CBE7-42C7-8DD2-6630257B1E30Q38156660-1BD52F3D-D38C-4E89-B2A5-679B7492ED6AQ38696649-F318665C-CF5B-4B30-A34C-1F0A3D5964EFQ39413582-9CD3813A-2526-4948-B70F-F1132C8834DCQ39596344-A154A47E-583A-45C0-8E50-4F27047E0F6CQ39979513-C94C5E66-53C8-4B56-919B-760E1EEE73D1Q40268569-53C5072F-6A03-4988-BD7C-AFA6DBA9BA07Q42575184-0BA6E262-06EC-441D-A053-4E5347749A2D
P2860
213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@en
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@nl
type
label
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@en
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@nl
prefLabel
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@en
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@nl
P2093
P1476
213Bi-[DOTA0, Tyr3]octreotide ...... in a preclinical animal model.
@en
P2093
Boudewijn J Krenning
Donna F Kusewitt
Inge R H M Konings
Jeffrey P Norenberg
Kayhan Garmestani
Larry K Kvols
Marion de Jong
Martin W Brechbiel
Tamara L Anderson
P304
P356
10.1158/1078-0432.CCR-05-1264
P407
P433
P577
2006-02-01T00:00:00Z